Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J App Pharm Sci. 2024; 14(4): 197-203


Formulation and in-vitro evaluation of electrospun microfibers for enhanced solubility of Olmesartan medoxomil

Sreenivas Patro Sisinthy, Siew En Chai, Shahnaz Majeed, Nur Najihah Izzati Mat Rani.




Abstract

Olmesartan medoxomil (OLM), which is a biopharmaceutical classification system class II drug has low aqueous solubility, resulting in its poor bioavailability and therapeutic efficacy. In this present study, OLM was formulated into electrospun microfibers to enhance its aqueous solubility and dissolution rate. OLM-loaded microfibers were formulated by using the electrospinning method using Eudragit RS 100 and Soluplus as carriers. The physicochemical characteristics of microfibers were evaluated by scanning electron microscopy (SEM), Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), drug content uniformity and in vitro dissolution studies. SEM and DSC analysis suggested that the electrospun microfibers were uniform and OLM is dispersed in an amorphous state. FTIR analysis showed no incompatibility between the drug and polymers in the microfibers. OLM content in the prepared OLM-loaded microfibers with Eudragit RS 100 and Soluplus was found to be 96.93 ± 0.03% and 93.67 ± 0.05% respectively. In vitro, dissolution concluded that Soluplus and Eudragit RS 100 increased OLM’s dissolution rate by three-fold and two-fold respectively. In conclusion, OLM had good compatibility with both the carriers and OLM’s dissolution rate was remarkably enhanced by formulating electrospun microfibers with Eudragit RS 100 and Soluplus.

Key words: electrospinning, microfiber, eudragit RS 100, soluplus, olmesartan






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.